Armata Pharmaceuticals Yönetim

Yönetim kriter kontrolleri 1/4

Şu anda CEO hakkında yeterli bilgiye sahip değiliz.

Anahtar bilgiler

Deborah Birx

İcra Kurulu Başkanı

US$1.4m

Toplam tazminat

CEO maaş yüzdesi	17.8%
CEO görev süresi	1.3yrs
CEO sahipliği	n/a
Yönetim ortalama görev süresi	less than a year
Yönetim Kurulu ortalama görev süresi	4.8yrs

Son yönetim güncellemeleri

Recent updates

CEO Tazminat Analizi

Deborah Birx'un ücretlendirmesi Armata Pharmaceuticals'un kazancına kıyasla nasıl değişti?
Tarih	Toplam Tazminat	Maaş	Şirket Kazançları
Jun 30 2024	n/a	n/a	-US$67m
Mar 31 2024	n/a	n/a	-US$80m
Dec 31 2023	US$1m	US$252k	-US$69m

Tazminat ve Piyasa: Deborah 'nin toplam tazminatı ($USD 1.41M ), US pazarındaki benzer büyüklükteki şirketler için ortalamanın üzerindedir ($USD 656.26K ).

Tazminat ve Kazançlar: Deborah şirketinin tazminatını şirket performansıyla karşılaştırmak için yeterli veri yok.

CEO

Deborah Birx (67 yo)

1.3yrs

Görev süresi

US$1,411,908

Tazminat

Dr. Deborah L. Birx, M.D., serves as CEO & Director of Armata Pharmaceuticals, Inc. since July 11, 2023. She is Member of Palantir Federal Advisory Board at Palantir Technologies Inc. since October 2022. S...

Liderlik Ekibi

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Deborah Birx	CEO & Director	1.3yrs	US$1.41m	Veri yok
Mina Pastagia	Chief Medical Officer	4.1yrs	US$463.75k	0.17% $ 143.5k
David House	Senior VP of Finance & Principal Financial Officer	less than a year	Veri yok	Veri yok
Peter Hubbard	Vice President of Operations	less than a year	Veri yok	Veri yok
Pierre Kyme	Chief Business Officer	less than a year	Veri yok	0.028% $ 23.5k

0.8yrs

Ortalama Görev Süresi

Deneyimli Yönetim: ARMP 'un yönetim ekibi deneyimli olarak kabul edilmiyor ( 0.8 yıl), bu da yeni bir ekibin varlığını gösteriyor.

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Deborah Birx	CEO & Director	1.3yrs	US$1.41m	Veri yok
Joseph Patti	Independent Director	5.5yrs	US$86.19k	0% $ 0
Jules Haimovitz	Independent Director	3.6yrs	US$74.88k	0% $ 0
Odysseas Kostas	Independent Director	4.8yrs	US$64.19k	0% $ 0
Athena Papas	Member of C16G2 Clinical Advisory Board	no data	Veri yok	Veri yok
Sarah Schlesinger	Independent Director	4.8yrs	US$66.19k	0% $ 0
Todd Peterson	Independent Director	5.1yrs	US$73.19k	0% $ 0
Robin Kramer	Independent Chairman of the Board	3.9yrs	US$105.50k	0% $ 0
James Bader	Member of C16G2 Clinical Advisory Board	no data	Veri yok	Veri yok
Ann Griffen	Member of C16G2 Clinical Advisory Board	no data	Veri yok	Veri yok
Mark Wolff	Member of C16G2 Clinical Advisory Board	no data	Veri yok	Veri yok
Domenick Zero	Member of C16G2 Clinical Advisory Board	no data	Veri yok	Veri yok

4.8yrs

Ortalama Görev Süresi

64yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: ARMP 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 4.8 yıldır).

Armata Pharmaceuticals Yönetim

Yönetim kriter kontrolleri 1/4

Anahtar bilgiler

Son yönetim güncellemeleri

Armata Pharmaceuticals Announces Principal Financial Officer Changes

Insufficient new directors

Armata Pharmaceuticals, Inc., Annual General Meeting, Jun 12, 2024

Armata Pharmaceuticals, Inc. Announces CFO Changes

Armata Pharmaceuticals, Inc. Announces Deborah L. Birx to Board of Directors

Armata Pharmaceuticals, Inc., Annual General Meeting, Aug 29, 2023

Recent updates

New major risk - Revenue and earnings growth

Consensus revenue estimates decrease by 32%, EPS upgraded

Armata Pharmaceuticals Announces Principal Financial Officer Changes

Second quarter 2024 earnings released: EPS: US$0.25 (vs US$0.098 loss in 2Q 2023)

Armata Pharmaceuticals Receives $5.25 Million of Additional Non-Dilutive Grant Funding from the U.S. Department of Defense to Support Ongoing diSArm Clinical Trial of AP-SA02

Armata Pharmaceuticals, Inc. Announces Completion of Enrollment of Phase 2 Tailwind Study of Inhaled Ap-Pa02 in Non-Cystic Fibrosis Bronchiectasis Subjects with Chronic Pulmonary Pseudomonas Aeruginosa Infection

Consensus EPS estimates fall by 43%

First quarter 2024 earnings: EPS and revenues miss analyst expectations

Insufficient new directors

Armata Pharmaceuticals, Inc., Annual General Meeting, Jun 12, 2024

New minor risk - Market cap size

Consensus EPS estimates fall by 52%

Full year 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Third quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Armata Pharmaceuticals Announces Presentation of Topline Data from SWARM-P.a. Clinical Study at the North American Cystic Fibrosis Conference

Armata Pharmaceuticals, Inc. Announces First Patient Dosed in the Phase 2A Portion of the Phase 1b/2a 'Disarm' Study of Ap-Sa02 in Adults with Bacteremia Due to Staphylococcus Aureus

Armata Pharmaceuticals, Inc. Announces CFO Changes

Consensus revenue estimates decrease by 44%, EPS upgraded

New minor risk - Revenue size

Second quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

New major risk - Share price stability

Armata Pharmaceuticals, Inc. Announces Deborah L. Birx to Board of Directors

Armata Pharmaceuticals, Inc., Annual General Meeting, Aug 29, 2023

First quarter 2023 earnings: EPS and revenues miss analyst expectations

Armata Pharmaceuticals, Inc. Announces Executive Changes

Full year 2022 earnings: EPS and revenues miss analyst expectations

Armata Pharmaceuticals, Inc. announced that it has received $30 million in funding from Innoviva Strategic Opportunities LLC

Armata Pharmaceuticals, Inc. announced that it has received $30 million in funding from Innoviva Strategic Opportunities LLC

Armata Pharmaceuticals Announces Completion of its Phase 1b/2a 'SWARM-P.a.' Study of Inhaled AP-PA02 in Cystic Fibrosis Subjects with Chronic Pulmonary Pseudomonas aeruginosa Infection

High number of new directors

Price target increased to US$8.00

Third quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Armata Pharmaceuticals, Inc., Annual General Meeting, Nov 16, 2022

Price target increased to US$8.00

Consensus forecasts updated

Second quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Armata Pharmaceuticals Announces Clearance of IND for Prosthetic Joint Infections

Armata Pharmaceuticals Announces First Patient Dosed in Phase 1b/2a 'diSArm' Study of AP-SA02 in Adults with Bacteremia Due to Staphylococcus Aureus

Consensus forecasts updated

High number of new directors

Armata Pharmaceuticals, Inc. announced that it has received $45 million in funding from Innoviva Strategic Opportunities LLC

Armata Pharmaceuticals, Inc. Announces CFO Changes

Consensus forecasts updated

Full year 2021 earnings: EPS misses analyst expectations

Armata Pharmaceuticals, Inc. Announces Clearance of Investigational New Drug Application to Initiate Phase 2 Clinical Trial of AP-PA02 in Non-Cystic Fibrosis Bronchiectasis

Price target increased to US$8.00

Armata Pharmaceuticals Provides Update on Pseudomonas Respiratory Programs

Third quarter 2021 earnings released: US$0.22 loss per share (vs US$0.31 loss in 3Q 2020)

Consensus forecasts updated

Price target increased to US$8.00

Consensus revenue estimates fall to US$666.7k

Armata Pharmaceuticals Inc. announced that it has received $20 million in funding from Innoviva, Inc.

Analysts update estimates

New 90-day high: US$5.07

New 90-day low: US$2.83

Earnings beat expectations, revenue disappoints

New 90-day high: US$3.94

Armata Pharmaceuticals Inc. Appoints Mina Pastagia as Vice President of Clinical Development

Armata Pharmaceuticals Announces Clearance of Investigational New Drug (IND) Application to Initiate Phase 1b/2a Clinical Trial of Lead Candidate AP-PA02 in Pseudomonas aeruginosa Infections

New 90-day low - US$3.26

Armata Pharmaceuticals Inc.(AMEX:ARMP) dropped from Russell Microcap Value Index

CEO Tazminat Analizi

CEO

Görev süresi

Tazminat

Liderlik Ekibi

Ortalama Görev Süresi

Yönetim Kurulu Üyeleri

Ortalama Görev Süresi